# Verdict

- Winner: tie
- Margin: 0.05
- Judge Confidence: low
- Needs Human Review: true

## Dimension Rationales
- Claim Quality: Both sides made the core claim correctly: the pilot does not justify full rollout because self-selection undermines causal inference. Side A was slightly more explicit about alternative explanations and control-group ambiguity, while Side B framed the operational next step a bit more cleanly.
- Evidence Discipline: Side A was marginally stronger because it stayed tightly anchored to stated evidence gaps and, after critique, removed an unsupported timeline claim. Side B was still disciplined overall, but its proposed randomized validation path assumes a cleaner transition to a new experiment without addressing whether existing pilot data should first be scoped for recoverable insight.
- Responsiveness To Critique: Both sides handled critique well and materially improved their final artifacts. Side A absorbed the feasibility challenge by splitting scoping from analysis, and Side B corrected the logical overstatement around drop-off versus retention.
- Internal Consistency: Side B ended slightly more internally coherent because its revised drop-off claim cleanly aligned with the survivorship-bias concern and the proposed validation path. Side A remained coherent, but its artifact sits partly between PRD and analysis memo, which creates a bit more structural tension.
- Decision Usefulness: Both artifacts are decision-useful because they block full rollout and specify a safer next step. Side A is more useful for immediate triage of the current evidence package, while Side B is more useful if the organization is ready to proceed directly to a clean randomized validation plan.

## Side Summaries
### Side A Strengths
- Provides the most rigorous decomposition of the current evidence gaps and a practical scoping-first path before committing to broader action.

### Side A Weaknesses
- Reads more like an evidence-review memo than a forward-operating PRD, which slightly weakens product-spec usefulness.

### Side B Strengths
- Translates the flawed pilot into a clean validation-gated rollout plan with crisp requirements and rollout gates.

### Side B Weaknesses
- Skips some of the operational nuance around whether existing data should be scoped before defaulting to a new randomized phase.

- Decisive Dimension: evidence_discipline

## Decisive Findings
- Side A more fully separated what is known from what is merely proposed, especially after revising its unsupported timing/cost implication.
- Side B improved its logical precision after critique, but its artifact still leans faster toward a new experiment without fully addressing whether the current pilot can be partially salvaged through scoped analysis.
- The overall quality gap remained too small to clear the minimum margin for a non-tie verdict.

## Uncertainty Payload

- Can Resolve With More Evidence: true
- Recommended Next Artifact: A human-adjudication note applying the benchmark scoring spec to the PRD-versus-analysis-structure tradeoff in this case.
- Recommended Next Action: Escalate this run for a human tie-break focused on artifact-type fit and the intended weighting of evidence rigor versus PRD operationalization.
- Escalation Recommendation: Escalate to human review, using the scoring spec to decide whether Side A's evidence-gating rigor or Side B's cleaner PRD framing better matches the benchmark objective.

### Uncertainty Drivers
- The final score gap is below the minimum margin for verdict.
- Both artifacts are strong, structurally compliant, and converge on the same practical recommendation to block full rollout.
- The benchmark asks for a PRD, and reasonable judges could differ on whether Side A's analysis-heavy structure or Side B's more implementation-oriented structure better fits that contract.
- There is no external scoring-spec text in the packet to disambiguate how heavily to weight PRD form versus evidence rigor.

### Disambiguation Questions
- In this benchmark, should a stronger score favor the artifact that most rigorously interrogates the current evidence package, or the artifact that more directly specifies the next controlled rollout plan as a PRD?

### Needed Evidence
- The detailed benchmark scoring guidance for how to trade off PRD form against analytical rigor.
- Any validator preference on whether the Recommended Next Artifact should be a scoping memo first or an experiment brief directly.
- Human adjudication on whether Side A's structure is acceptably PRD-like for this scenario.

## Rationale
This run is effectively a dead heat. Both sides correctly rejected full rollout, identified self-selection as the central causal threat, and used critique constructively to improve weak spots. Side A was slightly stronger on evidence discipline because it more carefully bounded what can be concluded from the current pilot and revised an unsupported feasibility claim. Side B was slightly stronger on internal coherence and PRD-style operationalization after tightening its drop-off logic. Because the remaining difference is narrow and turns largely on how the benchmark prioritizes analytical rigor versus PRD form, the margin does not clear the threshold for a clean winner.

